Microbiome Disease Pipeline Advances as 140+ Companies Develop Novel Therapies

The Microbiome Disease Pipeline is gaining significant momentum as pharmaceutical, biotechnology, and healthcare companies explore innovative approaches to address diseases associated with microbial imbalance and altered host-microbiome interactions. DelveInsight’s “Microbiome Disease Pipeline Insights 2026” report provides a comprehensive assessment of the evolving pipeline landscape, covering more than 140 companies and over 180 pipeline drugs across clinical and preclinical development stages.

The report evaluates emerging therapies according to product type, development stage, route of administration, and molecule type. It also highlights inactive, discontinued, and dormant programs, providing a broader view of ongoing innovation and potential opportunities within the microbiome therapeutic landscape.

Discover the latest drugs and treatment options in the Microbiome Disease Pipeline @ https://www.delveinsight.com/report-store/microbiome-disease-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Microbiome Disease Pipeline Shows Expanding Therapeutic Activity

The current Microbiome Disease Pipeline reflects growing interest in therapies designed to modify, restore, or utilize microbial communities to influence disease outcomes. In July 2026, Microbiome Health Sciences initiated a multicenter, randomized, double-blind, placebo-controlled study evaluating MHS-1031 alongside proton pump inhibitor therapy for patients experiencing GERD-related heartburn symptoms.

The study is designed to assess heartburn-free days based on patient-reported outcomes from the RESQ-eD questionnaire. Such developments demonstrate how microbiome-focused research is extending into gastrointestinal conditions and other therapeutic areas where microbial interactions may influence disease progression and treatment response.

DelveInsight's analysis identifies more than 140 active companies developing over 180 therapies, highlighting the breadth of innovation across the field.

Key Companies Driving Microbiome Disease Drug Development

Several companies are actively advancing therapeutic candidates across different stages of development. Prominent participants include MaaT Pharma, Qu Biologics, Biomica Ltd., Seres Therapeutics, Micro Viable Therapeutics, Metagen Therapeutics, Inc., Microbiotica, Enterome, Azitra, and Vedanta Biosciences.

These organizations are investigating different approaches, ranging from microbiome ecosystem therapies and microbial consortia to immune modulation and live bacterial products. Their development programs reflect the diverse strategies being explored to restore microbial balance, improve immune responses, strengthen epithelial barriers, and address infectious or inflammatory conditions.

Stay ahead with the most recent pipeline outlook for Microbiome Disease @ https://www.delveinsight.com/sample-request/microbiome-disease-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Promising Emerging Therapies in the Microbiome Disease Pipeline

The pipeline includes a wide range of emerging and established therapeutic candidates being assessed for different indications. Examples highlighted in the landscape include Omadacycline Injection, Estrogen Cream, Altreno, Benzoyl peroxide, Mirabegron, Solifenacin, and Dupilumab.

The diversity of these candidates illustrates the broad therapeutic relevance of microbiome-related research. Depending on the disease and mechanism involved, therapies may target microbial composition directly or influence pathways connected with inflammation, immunity, epithelial function, and host-microbe interactions.

MaaT 013 Advances Microbiome Ecosystem Therapy

MaaT 013, developed by MaaT Pharma, is a standardized, high-richness and high-diversity Microbiome Ecosystem Therapy designed to restore the relationship between the gut microbiome and the immune system. The therapy incorporates Butycore, a group of bacterial genera associated with immunoregulatory metabolites.

The candidate is being developed for steroid-resistant, gastrointestinal-predominant acute graft-versus-host disease. MaaT 013 has received Orphan Drug Designation from both the U.S. FDA and European Medicines Agency. It is currently in Phase III development, representing one of the more advanced programs within the microbiome therapeutic landscape.

QBKPN and BMC128 Explore Innovative Microbial Approaches

Qu Biologics is developing QBKPN SSI as an immune modulator intended to optimize immunity and barrier function in the lungs. Its clinical development focuses on restoring innate immune function and evaluating its potential role in respiratory infections and related outcomes. The candidate is currently in Phase II development for immunodeficiency disorders.

Meanwhile, Biomica Ltd. is advancing BMC128, a rationally designed microbial consortium consisting of four bacterial strains naturally found in the human intestinal tract. The candidate was developed using functional microbiome analysis and is designed to support immunological therapeutic responses and anti-tumor immune activity. BMC128 is currently being evaluated in Phase I development for colorectal cancer.

SER-155 and MVT-201 Expand the Pipeline Landscape

Seres Therapeutics is developing SER-155, a bacterial consortium designed using microbiome biomarker data, human cell-based assays, and disease models. The candidate aims to reduce the abundance of pathogenic bacteria, support gastrointestinal epithelial barrier integrity, and potentially reduce bloodstream infections and graft-versus-host disease. SER-155 has received FDA Fast Track Designation and is in Phase I development for bacteraemia.

Micro Viable Therapeutics is developing MVT-201, an orally administered capsule containing complete gut microbiota derived from a clinically validated healthy donor. The candidate is being investigated as a microbiota-based biological therapy and remains in the preclinical development stage for infectious diseases.

Microbiome Disease Pipeline Assessment and Therapeutic Segmentation